Using an extended multiplexed immunoassay for 71 cytokine/chemokine/growth factors in plasma, we detected significant differences in six Th2-related chemokines between AD patients and healthy subjects, as shown in Figure 1A. Five of these six chemokines are validated [48] as AD disease biomarkers: thymus and activation-regulated chemokine (TARC/CCL17), macrophage derived chemokine (MDC/CCL22), eosinophil-attracting chemokine (eotaxin-3/CCL26), cutaneous T cell attracting chemokine (C-TACK/CCL27), and monocyte chemoattractant protein-4 (MCP-4/CCL13). This evidence concerns the gene CCL22 and Alzheimer disease.